ライフサイエンスコーパス: antibody-positive

1 s was 17 (IQR: 6, 50) and 246 (19%) were HCV antibody positive.

2 were perinuclear antineutrophil cytoplasmic antibody positive.

3 Five children were antinuclear antibody positive.

4 nitially antibody negative HHCs, none became antibody positive.

5 ot identified as EHF patients were initially antibody positive.

6 Of 30 healthy blood donors, 20% were antibody positive.

7 Of 4713 patients, 652 (13.8%) were HCV antibody positive.

8 7 of 23 serum samples from patients remained antibody positive.

9 607/694 (87%) participants tested were HIV antibody positive.

10 of the 543 bonobo samples from six sites was antibody positive.

11 atient known to be isolated hepatitis B core antibody-positive.

12 129 (77%) were acetylcholine receptor antibody-positive.

13 imab group and 76 in the placebo group) were antibody-positive.

14 mABMR were usually sensitized, 60% being HLA antibody-positive.

15 her among those who were hepatitis B surface antibody positive (12.5%) as compared to those without d

16 ghing between 13 and 14 g least likely to be antibody positive (12.9%).

17 9), HCV RNA testing among those who were HCV antibody-positive (2 studies; OR, 1.83; 95% CI, 1.27-2.6

18 In the 5777 people who were HCV antibody positive, 2086 (34.4%) reported harmful or haza

19 393 (12%) partner participants were HCV antibody positive, 213 (54%) of whom had viraemia and 10

20 ce weighing less than 11 g most likely to be antibody positive (26.9%) and juvenile mice weighing bet

21 for hepatitis C virus (HCV), 180 tested HCV antibody positive (34%), and 108 were HCV-ribonucleic ac

22 e 5777 people who inject drugs that were HCV antibody positive, 440 (5.5%) were aware of their status

23 6.9% anti-HBc/anti-HBs (hepatitis B surface antibody) positive, 6.9% isolated anti-HBs positive, and

24 are (POC) tested 4293 individuals (10% [427] antibody-positive, 71% [299/419] RNA performed, 80% [241

25 Nineteen mothers were anti-Ro antibody positive, 8 anti-La antibody positive, and 7 ha

26 At baseline, 521 patients (45.4%) were HCV-antibody positive, 85 (7.4%) were hepatitis B surface an

27 sed reflex strategy screened 4654 (15% [679] antibody positive, 99% [670/679] RNA performed, 64% [433

28 lification test positive [NAT+, n = 2331] or antibody positive (Ab+)/NAT- [n = 1826]) based on recipi

29 Hepatitis C virus (HCV)-positive donors (antibody-positive [Ab + ] or nucleic acid test positive

30 y transplant recipients with donor-specific, antibody-positive ABMR >=365 days post-transplantation.

31 We selected 196 antinuclear antibody-positive adult SLE patients (age > or =20 years

32 Twenty antibody-positive adults were orally administered rNV VL

33 We studied HCV antibody-positive adults with HIV in the EuroSIDA study,

34 In contrast, nine cats became antibody positive after FIV vaccination but remained neg

35 erring the risk of anticitrullinated protein antibodies-positive and negative RA.

36 5 samples from eastern chimpanzees, 323 were antibody positive and 92 contained viral RNA.

37 nd congestive heart failure, was antinuclear antibody positive and had muscle biopsy findings "consis

38 hose HLA-identical donor was found to be HCV antibody positive and HCV RNA positive by polymerase cha

39 experimentally FIV-infected cats (n=5) were antibody positive and highly positive in the FIV PCR.

40 here was no survival rate difference between antibody-positive and -negative groups.

41 Antibody-positive and antibody-negative individuals were

42 Serum or plasma samples from HAV antibody-positive and antibody-negative individuals were

43 The prevalence of HCV antibody-positive and chronic HCV infection at accession

44 cted, HIV-negative persons, the frequency of antibody-positive and genotype-concordant couples is 2.8

45 ant clinical difference between anti-U11/U12 antibody-positive and negative cohorts was the prevalenc

46 of vertical HCV infection to children of HCV antibody-positive and RNA-positive women was 5.8% (95% c

47 The most prevalent responses in antibody-positive and type 1 diabetic subjects were to p

48 risk were generated for children born to HCV antibody-positive and viremic women, aged >/=18 months,

49 topenia or thromboembolic events between the antibody-positive and-negative groups.

50 rs were anti-Ro antibody positive, 8 anti-La antibody positive, and 7 had clinical autoimmune disease

51 e living with HIV, 52.3% (42.4-62.1) are HCV-antibody positive, and 9.0% (5.1-13.2) are HBV surface a

52 Fifty-six patients were anti-C1q antibody positive, and Ig subclass analysis indicated a

53 the presence of one or more M. ovipneumoniae antibody-positive animals and the occurrence of current

54 Forty-four specimens from 78 antibody-positive animals had sufficient residual volume

55 was detected in cervical secretions of serum antibody-positive animals, predominantly against MgpB an

56 lly more severe cyclic-citrullinated peptide antibody-positive (anti-CCP+) RA.

57 Patients were divided into antibody-positive (AP) (n = 11) and antibody-negative (A

58 umab in adult patients with anti-aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum

59 th muscle cell actin and anti-rat macrophage antibody-positive areas were significantly reduced withi

60 Participants who were HCV antibody-positive at enrolment and those with HCV antibo

61 lgorithms performed well in the diagnosis of antibody-positive autoimmune encephalitis, but the paedi

62 .97-1.00) for the diagnosis of children with antibody-positive autoimmune encephalitis, good (0.59, 0

63 initial workup of 23 patients proven to have antibody-positive autoimmune encephalitis.

64 at come from donors who are hepatitis B core antibody positive because of a fear of transmission of h

65 pregnancies in 16 888 people who tested HCV antibody-positive between 1999 and 2021.

66 vidual testing, whereas neither recipient of antibody-positive blood components that were reactive on

67 antibodies, raising the question whether WNV antibody-positive blood components with low levels of WN

68 h follow-up, we examined the effect of HHV-8 antibody-positive blood on transfusion recipients surviv

69 multiple transfusions), recipients of HHV-8 antibody-positive blood stored </=4 days ("short-stored"

70 Transfusion with short-stored HHV-8 antibody-positive blood was associated with an increased

71 ted mortality following transfusion of HHV-8 antibody-positive blood.

72 ents, 471 (43.1%) were transfused with HHV-8 antibody-positive blood.

73 were HCV antibody negative, 34 who were HCV antibody positive but RNA negative, and 112 who were HCV

74 70 (3.5%) of these infants were rubella IgM antibody positive, but none of the infants had features

75 with confirmed CMV infection were CMV-total antibody positive, but only 1 of 3 had CMV-IgM antibody.

76 antigen in acquisition with age: rapid (>80% antibody positive by age 20 years, 5 antigens), moderate

77 Six antibody-positive cancer patients had p53 mutations, whe

78 -DQA1*05-DQB1*02), anti-Jo-1 and anti-PM-Scl antibody-positive cases have differing IIM clinical phen

79 All MOG antibody-positive cases were included in our study, whic

80 In both experiments, antibody-positive cats were protected from clinical dise

81 myeloma and anti-HLA class II donor-specific antibody-positive chronic active AMR 13 years after tran

82 35 HIV-1-positive patients with KS, 60% were antibody positive, compared with 27% of 33 HIV-1-positiv

83 nd endogenous human IgG and the neutralizing antibody positive-control (NAb-PC) in the BEAD eluates.

84 al transplant recipients who are hepatitis C antibody positive do not have an increased risk of death

85 e of organs obtained from a hepatitis B core antibody positive donor.

86 Patients receiving HCV antibody-positive donor hearts without detectable circul

87 ive recipients who received kidneys from HCV antibody positive donors (D-HCV) (n=48); and (3) HCV neg

88 Additionally, there were 2,635 LTs using HCV antibody-positive donors (DAb(+) ): 2,378 DAb(+) /R(+) a

89 ted in five bone marrow samples from healthy antibody-positive donors.

90 ge of 56 +/- 11 SD) received hearts from HCV-antibody-positive donors.

91 -embedded tissues (FFPE) from donor-specific antibody-positive (DSA+) renal allograft recipients prom

92 y-naive patients with acetylcholine receptor antibody-positive early-onset MG.

93 Of 101 FIV antibody-positive feline blood specimens submitted for F

94 o measure 16 separate ACPAs in sera from 111 antibody-positive first-degree relatives who were positi

95 found in patients having an AMI and who were antibody positive for dUTPase (ANOVA p=0.008; 369 +/- 18

96 onically infected with HCV, most of whom are antibody positive for HCV E2.

97 RNA positive and 10 nonviremic samples were antibody positive for peptides or NS4AB.

98 mon; 17.7% (95% CI 15.0-20.7) of people were antibody-positive for hepatitis C virus, with lower esti

99 fection, and predicts individuals may remain antibody positive from natural infection beyond 500 days

100 ptical density (OD) that distinguishes UL144 antibody-positive from antibody-negative sera was establ

101 48 patients with acetylcholine receptor antibody-positive gMG were treated in 12 centres.

102 spholipid antibodies in lupus patients (4.8% antibody-positive group vs. 16.6% in the antibody-negati

103 nificantly increased in the anti-U11/U12 RNP antibody-positive group.

104 ts, 3.4% (15 of 447) of those who were HSV-1 antibody positive had a subsequent negative result while

105 Sixty patients who were anti-topo I antibody positive had diffuse cutaneous SSc (dcSSc) with

106 Patients who were anti-CarP antibody positive had significantly more disability over

107 renal allografts from hepatitis B virus core antibody-positive (HBcAb(+)), hepatitis B virus surface

108 eradicated or persists at a low level in HCV antibody-positive HCV RNA-negative individuals.

109 between those who were transplanted from HCV antibody-positive (HCV+) vs. HCV antibody-negative donor

110 recombinant immunoblot assay-confirmed, HCV antibody-positive (HCV+), allogeneic blood donors from 1

111 evaluation of antibody-directed therapies in antibody-positive heart failure.

112 HCV-antibody negative recipients of HCV-antibody positive hearts were identified from January 1,

113 The existence of initially antibody-positive HHCs suggests that mild cases of Ebola

114 One H5 antibody-positive household contact, with no history of

115 clear cells (PBMCs) pretreated with anti-HLA antibody positive (HS) or negative (NC) sera to measure

116 us mammalian cell systems, reacted with KSHV antibody-positive human sera, resulting in a punctate nu

117 nd no evidence of positive associations with antibody-positive hypothyroidism, hyperthyroidism, AIT,

118 Eight islet cell antibody-positive (ICA+) relatives of IDDM patients were

119 We deemed a patient to be antibody positive if their serum, their CSF, or both tes

120 ected from PWs were considered to be anti-H5 antibody positive if they were positive by both microneu

121 uses/infants born to mothers with anti-Ro/La antibodies (positive IgG).

122 y significant associations between anti-Jo-1 antibody-positive ILD and elevated serum levels of C-rea

123 ease-specific associations between anti-Jo-1 antibody-positive ILD and serum levels of CRP as well as

124 the serum proteins associated with anti-Jo-1 antibody-positive ILD.

125 tely 4.1 (3.4-4.9) million persons, were HCV antibody-positive (indicating past or current infection)

126 Antibody-positive individuals exhibited robust and broad

127 HCV antibody-positive individuals were 3-fold more likely to

128 econd study determined the proportion of EBO antibody-positive individuals who lived in villages surr

129 The first study determined the proportion of antibody-positive individuals who were self-identified f

130 determined the existence of ILD in anti-Jo-1 antibody-positive individuals whose data were accumulate

131 Among the 90 anti-Jo-1 antibody-positive individuals with sufficient clinical,

132 In this large cohort of anti-Jo-1 antibody-positive individuals, the incidence of ILD appr

133 um thyroiditis in women who are or have been antibody positive is unknown.

134 id factor- and/or anti-citrullinated protein antibody-positive juvenile idiopathic arthritis.

135 umatoid factor or anti-citrullinated protein antibody-positive juvenile idiopathic arthritis.

136 levels were significantly higher in sera of antibody-positive lung cancer patients compared with ant

137 itive, but 18 ocular SNMG patients, 105 AChR antibody positive MG patients, and 108 controls were neg

138 of TLS was found in anti-double-stranded DNA antibody-positive mice, and the structures were organize

139 ar-old boy with P-antineutrophil cytoplasmic antibody-positive microscopic polyangiitis, resulting in

140 virus antibody-negative and two rhadinovirus antibody-positive monkeys were used for these experiment

141 No risk was found for children of TPO-antibody-positive mothers (n=308).

142 Of 155 singleton infants born to HCV antibody-positive mothers, 13 (8.4%) were HCV infected.

143 ndex, may differentiate PML risk in anti-JCV antibody-positive MS patients with no prior immunosuppre

144 levels and PML risk was examined in anti-JCV antibody-positive multiple sclerosis (MS) patients from

145 oline receptor [AChR; acetylcholine receptor antibody positive myasthenia gravis (AChR-MG)] by the ra

146 udies confirm three major phenotypes in MuSK antibody positive myasthenia gravis (MMG) patients: indi

147 bodies to muscle specific kinase [MuSK; MuSK antibody positive myasthenia gravis (MuSK-MG)] make up a

148 n how muscle specific tyrosine kinase (MuSK) antibody positive myasthenia gravis results in neuromusc

149 nt of muscle-specific tyrosine kinase (MuSK) antibody positive myasthenia gravis will be reviewed.

150 a diagnosed as having acetylcholine receptor antibody-positive myasthenia gravis and 1998 race/ethnic

151 ggest an incidence of acetylcholine receptor antibody-positive myasthenia gravis of up to 29 cases pe

152 ibrosis and anti-signal recognition particle antibody-positive myositis.

153 Seven antinuclear antibody-positive, nephritic female (SWR x NZB)F(1) (SNF

154 ivity (P < 0.05) in rods and neuronal nuclei antibody-positive neuronal density of 50% (P < 0.05) wer

155 observational case series of 14 aquaporin-4 antibody positive NMO and NMO spectrum disorder patients

156 to Wingerchuk's 2006 criteria or aquaporin-4 antibody-positive NMO spectrum disorder (NMOSD).

157 six of the 1000 (7.6%) participants were HCV antibody positive; none were confirmed by detection of H

158 n of liver grafts from DCD HCV - and DCD HCV antibody-positive nucleic acid test negative donors.

159 reported having sexual partners who were HIV antibody positive (odds ratio = 1.36, 95% confidence int

160 macaques with RRV, whether the animals were antibody positive or negative at the time of virus inocu

161 erences between anti-beta- and/or anti-gamma-antibody positive or negative patients with respect to b

162 d, placebo-controlled trial, 819 antinuclear antibody-positive or anti-double-stranded DNA-positive S

163 us immune response against SARS-CoV-2 (serum antibody-positive or serum antibody-negative).

164 surface antibody level >/=10 mIU/mL or core antibody positive, or by documented vaccination.

165 were assigned to either the positive cohort (antibody positive, or previous positive PCR or antibody

166 ection in heart transplant recipients of HCV-antibody positive organs is not known.

167 transplant recipients transplanted with HCV antibody-positive organs.

168 etween July 2014 and March 2017, 402 HIV/HCV antibody-positive participants were enrolled (95% male [

169 ccination at age 6 months and among maternal antibody-positive participants who started vaccination a

170 One antibody positive patient (EMA in isolation) declined du

171 ted purified plasma IgG from either a CASPR2-antibody-positive patient (n = 10 mice) or healthy indiv

172 A 55-year-old, JC virus (JCV) antibody-positive patient with multiple sclerosis who di

173 5 leucine-rich, glioma inactivated 1 protein-antibody positive patients (P < 0.0001), who predominant

174 tumour associations in 96 potassium channel antibody positive patients (titres >400 pM).

175 dies to FCS (median initial CD4 count in FCS antibody positive patients = 362.0/microL v median initi

176 42.9% and 63.9% of the DP antibody positive patients had DR/DQ antibodies among th

177 MuSK antibody positive patients represent a unique subset of

178 The 86% frequency of HLA-DQ7 in the antibody positive patients was significant compared with

179 In this study, vimentin antibody positive patients were screened for the presenc

180 ndistinguishable from acetylcholine receptor antibody positive patients, prominent faciopharyngeal we

181 We report 12 aquaporin-4 antibody-positive patients (12% of seropositive Mayo Cli

182 idence of rejection at 1 month was higher in antibody-positive patients (26%) than in antibody-negati

183 We analyzed 36 liver samples from HCV antibody-positive patients (30 from patients with chroni

184 the survival rate was even lower among MICA antibody-positive patients (87.8+/-2.4%) than among MICA

185 sed on viral load reflex testing of anti-HCV antibody-positive patients (known as one-step diagnosis)

186 In anti-JCV antibody-positive patients (n=21 696), estimated cumulat

187 The 3 retrospectively identified NMDAR antibody-positive patients also had evidence of relapsin

188 g DNA obtained from 318 anti-topoisomerase I antibody-positive patients and 561 healthy controls, all

189 We identified prospectively 52 antibody-positive patients and collated their clinical f

190 HCV RNA was detected in 85% of HCV antibody-positive patients by the whole-blood method com

191 should be made on whether anticoagulation in antibody-positive patients could ameliorate this catastr

192 Antibody-positive patients had lower PANSS positive, PAN

193 Conclusion: Nonviremic HCV antibody-positive patients have a liver biopsy that is u

194 ombocytopenia and thrombosis (HIT), but many antibody-positive patients have normal platelet counts.

195 Moreover, studies of AQP4-antibody-positive patients have revealed that brain lesi

196 For anti-JCV antibody-positive patients in this pooled cohort, cumula

197 ponses in an ELISPOT assay (p = 0.008 versus antibody-positive patients not experiencing ABMR).

198 Whereas antibody-positive patients rarely developed prominent br

199 One hundred antibody-positive patients received a transplant.

200 arly rejection seemed to be more frequent in antibody-positive patients regardless of whether the ant

201 hed controls in each of the 2 antiendomysial antibody-positive patients tested.

202 oral rejection were not more frequent in the antibody-positive patients than in the controls.

203 RT-PCR is a valuable adjunct to serology in antibody-positive patients to distinguish resolved from

204 hich occurred in 79% of the anti-U11/U12 RNP antibody-positive patients versus 37% of the anti-U11/U1

205 04-2005), the prevalence of anti-U11/U12 RNP antibody-positive patients was 15 of 462 (3.2%).

206 The median survival for p53 antibody-positive patients was 51 months (95% CI, 23.5 t

207 When the 379 antibody-positive patients were further tested with beta

208 Anti-topoisomerase I antibody-positive patients were more likely to be never

209 Myelin-oligodendrocyte glycoprotein antibody-positive patients were more likely to have conu

210 No anti-p140 antibody-positive patients were positive for other recog

211 Nineteen (86%) of the antibody-positive patients were viremic (HCV RNA positiv

212 ows further risk stratification for anti-JCV antibody-positive patients who have not previously taken

213 y-two percent of respondents would refer HCV antibody-positive patients with abnormal transaminase le

214 Two anti-glutamic acid decarboxylase antibody-positive patients with SPS had an autologous he

215 Anti-topo I antibody-positive patients with SSc with a rapid STPR ha

216 For anti-JCV antibody-positive patients without previous immunosuppre

217 oach to the management of 2 hypothetical HCV antibody-positive patients, 1 with elevated and the othe

218 Of interest, these antibody-positive patients, although lacking antiphospho

219 (AChR) antibody levels decreased in two AChR antibody-positive patients, and anti-MuSK antibody level

220 An entire subset of antibody-positive patients, anti-N-methyl-d-aspartate re

221 For 60% of the donor-specific antibody-positive patients, antibodies were detected bef

222 ments demonstrated that the IgG from GABARAP antibody-positive patients, but not control IgG, signifi

223 responses were observed against NY-ESO-1 in antibody-positive patients, regardless of their HLA prof

224 However, in alloimmunized lymphocytoxic antibody-positive patients, the immediate increment to U

225 Among antibody-positive patients, the mean +/- SD number of ne

226 risk of PF4/heparin immunization and, among antibody-positive patients, the risk of subsequent "brea

227 returned on 44 N-methyl-d-aspartate receptor antibody-positive patients, we identified a high proport

228 HLA-DR1 and DR4 haplotypes is reduced among antibody-positive patients.

229 pes for more appropriate treatment for these antibody-positive patients.

230 ated PML patients and 2,522 non-PML anti-JCV antibody-positive patients.

231 embranous GN, and antineutrophil cytoplasmic antibody-positive pauci-immune GN.

232 consecutive patients with antimitochondrial antibody-positive PBC who had an incomplete response to

233 cal tests in patients with antimitochondrial antibody-positive PBC who responded incompletely to trea

234 th HCV RNA and an estimated 0.38 million HCV antibody-positive persons and 0.25 million HCV RNA-posit

235 -specific CD4+ T-helper-cell response in HCV antibody-positive persons who lack detectable plasma vir

236 Among antibody-positive persons, the efficacy of natural infec

237 ity of HLA alloantibodies was studied in 128 antibody-positive, potential kidney transplant recipient

238 51 deceased donors) patients (donor-specific antibody positive, PRA>80%) were desensitized using IVIG

239 th anti-Bartonella serum and kittens born to antibody-positive queens with Bartonella henselae to det

240 demonstrated that anti-citrullinated protein antibody positive RA has a specific association with env

241 PN22 with the development of anti-citrulline antibody-positive RA (odds ratio [OR] 1.49; P=.00002), u

242 dy: 86 (48.9%) of 176 patients with anti-CCP antibody-positive RA had at least 1 SE allele, compared

243 ng in the risk of anti-citrullinated protein antibody-positive RA.

244 Antibody-positive reactions to granulocytic Ehrlichia sp

245 of adult renal allograft recipients: (1) HCV antibody positive recipients (R-HCV) (n=32); (2) HCV neg

246 HCV antibody-positive recipients (n = 520, 2.1%) had stable

247 in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia grav

248 Many JC virus antibody-positive relapsing-remitting multiple sclerosis

249 5 of 13 type 1 diabetic subjects and 4 of 6 antibody-positive relatives exhibited greater numbers of

250 determined autoantibodies among cytoplasmic antibody-positive relatives is associated with eligibili

251 D8(+) T-cell response in type 1 subjects and antibody-positive relatives.

252 ed thyroglobulin level without thyroglobulin antibodies, positive results on recent fine-needle aspir

253 bility of G2 and G3 EIAs to confirm anti-HCV antibody-positive results.

254 stological findings were compared between RR antibody positive (RR+) and negative (RR-) patients.

255 Ten glycine receptor antibody positive samples were also identified in a retr

256 The antibody-positive samples represented 76 individuals fro

257 Antibody-positive samples were tested for induction of p

258 n proteins against consecutive antinucleolar antibody-positive sera (HEp-2 cell substrate) collected

259 Antibody-positive sera from 84 mothers of children with

260 ibodies was proved using five representative antibody-positive sera in a complement-dependent cytotox

261 leolus, nucleolar staining by many anti-RNAP antibody-positive sera is not always observed.

262 Antibody-positive sera resulted in downregulation of syn

263 All 18 anti-RNAP I/III antibody-positive sera showed nuclear speckled patterns,

264 Nucleolar staining by anti-RNAP antibody-positive sera was examined by double staining w

265 The anti-OKT3 antibody-positive sera were screened additionally by flo

266 were found in 11 (10%) of 108 antinucleolar antibody-positive sera.

267 r than 1% (2 of 227) of those who were HSV-2 antibody positive seroreverted.

268 Finally, pooled, nonneutralizing SIV-antibody-positive serum, shown in a previous study to pr

269 One hundred seventy-two HCV antibody-positive, serum HCV RNA-negative patients under

270 he effects of rheumatoid factor, antinuclear antibodies, positive skin allergen tests, or IgE concent

271 her hand, such as antineutrophil cytoplasmic antibody-positive small vessel diseases, is largely rest

272 CI 89 to 95%) when excluding Leishmania spp. antibody positive specimens.

273 mens tested in MDM culture, 7 (88%) of 8 WNV antibody-positive specimens and 12 (100%) of 12 WNV anti

274 an collection-to-result turnaround times for antibody-positive specimens from 84 h (IQR 58-120) to 45

275 dy-negative specimens and 10 (36%) of 28 WNV antibody-positive specimens were infectious.

276 wed significant association with anti-topo I antibody-positive SSc in white patients (odds ratio [OR]

277 wed significant association with anti-topo I antibody-positive SSc in white patients (OR 2.03, 95% CI

278 Sc, OR 1.63, 95% CI 1.0-2.6; for anti-topo I antibody-positive SSc, OR 2.33, 95% CI 1.5-3.7).

279 association in ACA-positive and anti-topo I antibody-positive SSc.

280 Ten out of thirteen of the antibody-positive subjects agreed to undergo endoscopy.

281 er peptides recognized by type 1 diabetic or antibody-positive subjects included GFAP(143-151), IGRP(

282 The five HCV antibody-positive subjects who were negative by whole-bl

283 associated with ACA-positive and anti-topo I antibody-positive subsets of SSc and represents a risk f

284 h antitopoisomerase (ATA) and anticentromere antibody-positive subsets of SSc, respectively, than wit

285 A total of 564 antibody-positive survivors (320 [56.7%] female; mean [S

286 A total of 966 EBOV antibody-positive survivors and 2350 antibody-negative c

287 h a history of injection drug use and an HCV antibody-positive test result during follow-up.

288 e before left lateral ventricle injection of antibody-positive (test) or healthy (control) immunoglob

289 re were more steroid-resistant rejections in antibody-positive than in antibody-negative patients.

290 diagnostic criteria (i.e., antimitochondrial antibody-positive titer >/=1 in 40, cholestatic liver bl

291 in patients with coronary artery disease and antibodies positive to CPn.

292 effect of each additional short-stored HHV-8 antibody-positive transfusion was 1.79 (95% CI, 1.33-2.4

293 ective studies in which patients known to be antibody positive underwent transplantation.

294 Two probands were antineutrophil cytoplasmic antibody positive vs. 1 of 27 unaffected relatives (P <

295 SSc patients (n = 212) who were anti-topo I antibody positive were divided into 5 subgroups based on

296 arch 2017, 402 participants who were HIV/HCV antibody positive were enrolled (95% male [80% gay and b

297 c recipients who were pretransplantation CMV antibody positive were longitudinally studied for circul

298 ose who knew that the source subject was HIV antibody positive were more likely to recruit their sour

299 e of prior exposure to HBV (hepatitis B core antibody-positive), whereas 5.8% (95% confidence interva

300 by serosurveillance, as well as a number of antibody positive wild boar on both sides of the border